Latest CervoMed News & Updates

See the latest news and media coverage for CervoMed. We track all announcements, press releases, and industry mentions in real time, all in one place.

CervoMed

Clinical-stage biotechnology company developing treatments for age-related brain disorders

cervomed.com

Headquarters: Boston, United States
Founded year: 2023
Company type: Public company
Number of employees: 20–50

Last updated Today

Latest news about CervoMed

In short: CervoMed secured $10.5M in financing and aligned with the FDA on a Phase 3 trial design for its lead drug candidate, neflamapimod.

Company announcements

Yesterday CervoMed

CervoMed closes $10 million registered direct offering

The offering of 2.5 million shares at $4.00 per share was placed by H.C. Wainwright & Co. and proceeds will be used for working capital.

June 10 CervoMed

CervoMed announces private placement financing and partnering plan

The $10.5M raise extends runway to Q2 2027 and supports partnership to move neflamapimod into Phase 3 for DLB.

May 18 CervoMed

CervoMed reports Q1 2026 financial results and corporate updates

Cash at $12.9M, net loss $8.0M, and progress on Phase 3 DLB trial and other programs.

April 7 CervoMed

CervoMed announces neflamapimod update and panel participation

The update includes MRI analyses from Phase 2b, regulatory alignment, and finalized Phase 3 design. Additional data at AAN meeting.

Media coverage

June 18 Yahoo Finance

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously...

June 18 Yahoo Finance

CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)

CervoMed Inc. (NASDAQ:CRVO) shares climbed 20% on Thursday after the company announced it had received a notice of allowance from the U.

June 16 Timothy Sykes

CRVO Stock Explodes As Insider Buy Fuels Biotech Momentum

CervoMed Inc. surged as promising neurodegenerative trial data boosted sentiment; stocks have been trading up by 19.95 percent. Key Takeaways CervoMed is raising about $10.5M...

June 10 Yahoo Finance

CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in...

Never miss news about CervoMed

Track CervoMed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

CervoMed competitors & trending companies

Browse news for competitors to CervoMed and other trending companies.